BioCentury | Apr 7, 2021
Distillery Therapeutics

eIF4E identified as target in obesity, fatty liver disease

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; liver disease Reducing levels of eIF4E or lowering the RNA cap-binding protein’s activity by blocking its phosphorylation could treat obesity...
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...
BioCentury | Apr 3, 2021
Product Development

Target diversity in the CAR NK and CAR NKT pipeline: Data Byte

Developers of CAR NK and CAR NKT cell therapies for cancer are collectively casting a wide net, with the roughly two dozen programs in development mapping to at least 10 targets across both solid and hematologic tumors....
BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

Though nearly every Chinese CAR T developer is prioritizing autologous programs, the key to expanding access to the modality on the price-sensitive China market is likely to be the next-generation platforms...
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

Cross-border company AffaMed now has more than $170 million in series B funding and the backing of Lake Bleu Capital to pair with its hiring of one of China’s most prominent dealmakers, Ji Li,...
BioCentury | Mar 19, 2021
Product Development

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

Years before the novel coronavirus began cutting its lethal course across nearly every continent on earth, scientists and senior executives at leading biopharmaceutical companies were discussing ways of accelerating the design, efficiency and pace of...
BioCentury | Mar 12, 2021
Product Development

COVID-19 Quick Takes: J&J vaccine authorized in EU as some EMA states pause AZ vaccine deployment; plus Genentech, Moderna, Novavax, Merck-Ridgeback, Atea and SerImmune

The European Commission granted conditional marketing authorization to COVID-19 Vaccine Janssen on Thursday, hours after EMA’s CHMP issued a positive recommendation for application. The single-shot adenoviral vector vaccine from Johnson & Johnson (NYSE:JNJ) is the fourth COVID-19...
BioCentury | Mar 10, 2021
Management Tracks

Ex-BARDA Director Bright joins Rockefeller Foundation; plus Lilly, Q32 Bio, Apollomics, Axial and Grip

Rick Bright joined The Rockefeller Foundation as SVP of pandemic prevention and response to establish an institute that seeks to prevent future pandemics by responding to the earliest signs of a disease outbreak and stopping...
BioCentury | Mar 6, 2021
Product Development

The pace of new modality approvals is picking up

Last week’s FDA approval of Sarepta’s Amondys 45 marks the ninth new modality drug to be approved in the last year, a sign that the pace of new therapeutic formats making it to...
BioCentury | Mar 3, 2021
Product Development

With Kymera’s clinical debut, targeted protein degradation gets its first RCT

As Kymera becomes the second company to bring a targeted protein degrader to the clinic, the company’s choice to start outside oncology is enabling it to gather a broader array of data than Arvinas’ single-arm,...
Items per page:
1 - 10 of 2241